Abstract
Relapse remains the most common cause of treatment failure after hematopoietic cell transplantation for acute myeloid leukemia. Inability to achieve hematologic complete remission has been a barrier to transplant for patients with refractory disease. We describe six children with refractory myeloid disease undergoing transplant in chemotherapy-induced aplasia, as a strategy to facilitate curative therapy in refractory patients. Clofarabine- or high-dose cytarabine-based chemotherapy regimens were used to achieve marrow aplasia, followed by reduced-intensity conditioning and allogeneic transplant before hematologic recovery. Long-term disease control was achieved in five, with one transplant-related mortality, suggesting the feasibility of this approach.
Original language | English (US) |
---|---|
Article number | e27481 |
Journal | Pediatric Blood and Cancer |
Volume | 66 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2019 |
Externally published | Yes |
Keywords
- acute myeloid leukemia
- hematopoietic cell transplantation
- myelodysplasia
- pediatrics
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology